Metraipolis › archive › dc_39e2170bcc88
[Glofitamab for relapsed/refractory B-cell lymphoma: analysis of efficacy and influencing factors] — Europe PMC PMID:42409737
- Source
- Europe PMC (chi)
- Original
- https://europepmc.org/article/MED/42409737
- DOI
- 10.3760/cma.j.cn121090-20260104-00002
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-02T21:58:42.523Z
- SHA-256 of the archived text
f7acc06a924b65c7bf660151fae2b77cc3ed78f53c48299c9477807b11c8d6a7- Stable URL of this page
https://metraipolis.com/documento/dc_39e2170bcc88
How to cite
[Glofitamab for relapsed/refractory B-cell lymphoma: analysis of efficacy and influencing factors] — Europe PMC PMID:42409737 — Europe PMC (chi), https://europepmc.org/article/MED/42409737 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_39e2170bcc88 (Metraipolis archive dc_39e2170bcc88, sha256 f7acc06a924b65c7bf660151fae2b77cc3ed78f53c48299c9477807b11c8d6a7)
BibTeX
@misc{dc39e2170bcc88,
title = {[Glofitamab for relapsed/refractory B-cell lymphoma: analysis of efficacy and influencing factors] — Europe PMC PMID:42409737},
howpublished = {Europe PMC (chi)},
url = {https://europepmc.org/article/MED/42409737},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_39e2170bcc88; sha256 f7acc06a924b65c7bf660151fae2b77cc3ed78f53c48299c9477807b11c8d6a7},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42409737. Agents can read the archived copy with the MCP tool read_document.